triple negative breast cancer; (ER-, PR-, HER2-)
Jump to navigation
Jump to search
Laboratory
- see breast cancer
Management
- triple negative (ER/PR receptor negative, HER2 negative) breast cancer responds to neoadjuvant chemothrapy[1]
- anthracycline-base chemotherapy for early stage triple-negative breast cancer (ER-, PR-, HER2-)[1]
- neoadjuvant chemotherapy for triple negative tumors uses standard chemotherapy (see chemotherapy for breast cancer)[1]
- atezolizumab (Tecentriq) FDA-approved for treatment of unresectable locally advanced or metastatic triple-negative breast cancer in tumors expressing PD-L1[2]
- also see breast cancer
More general terms
References
- ↑ 1.0 1.1 1.2 1.3 Medical Knowledge Self Assessment Program (MKSAP) 17, 18. American College of Physicians, Philadelphia 2015, 18.
- ↑ 2.0 2.1 FDA Approval Notice. March 8, 2019 FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm633065.htm